Quoin Pharmaceuticals Ltd Stock Price, News & Analysis

Quoin Pharmaceuticals (NASDAQ: QNRX) has announced the expansion of its ongoing Netherton Syndrome (NS) clinical trials to include two additional sites in the United Kingdom. The new sites are Great Ormond Street Hospital and St. Thomas' Hospital in London, both recognized as centers of excellence for treating NS patients. A Principal Investigator has been appointed, and a Clinical Research Organization has been engaged for the UK studies.

These sites, along with the previously announced site in Saudi Arabia, will operate under Quoin's open Investigational New Drug (IND) application with the US FDA. The company is also preparing to open additional sites in Western and Eastern European countries with available NS patient cohorts.

Quoin is currently conducting two clinical trials evaluating QRX003, a topical lotion, for the treatment of Netherton Syndrome. The company aims to complete enrollment in both studies rapidly to potentially deliver the first approved treatment for this rare, inherited genetic disease.

Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company, announced significant insider share purchases by its co-founders. CEO Michael Myers acquired 37,894 American Depositary Shares (ADSs) at prices ranging from $0.619 to $0.7974 per ADS on September 3-4, 2024. Similarly, COO Denise Carter purchased 37,735 ADSs between $0.6253 and $0.7965 per ADS during the same period.

These insider purchases are viewed as a strong signal of leadership confidence in Quoin's growth trajectory and commitment to delivering long-term shareholder value. The company focuses on developing and commercializing novel treatments for rare and orphan diseases, aiming to address unmet needs in underserved patient populations globally.

Quoin Pharmaceuticals (NASDAQ: QNRX) has provided a corporate update and announced financial results for Q2 2024. Key highlights include:

1. Research agreement with University College Cork to develop topical rapamycin formulations.
2. Expansion of Netherton Syndrome clinical trials internationally.
3. Plans to initiate a clinical study in Peeling Skin Syndrome.
4. Continued evaluation of M&A opportunities in rare and orphan diseases.

Financial highlights:
- Cash position of $12.6 million as of June 30, 2024.
- Net loss of $2.0 million for Q2 2024, compared to $2.1 million in Q2 2023.
- Net loss of $4.3 million for H1 2024, compared to $4.7 million in H1 2023.

Quoin Pharmaceuticals (NASDAQ: QNRX) has announced plans to initiate a clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome (PSS), a rare autosomal disease with no approved treatment. The study will focus on a pediatric patient, with the company actively exploring additional clinical sites in other countries.

QRX003, Quoin's most advanced pipeline product, is already being tested in two late-stage clinical trials for Netherton Syndrome (NS) in the United States under an FDA-approved IND. The company aims to expand QRX003's development into PSS, leveraging potential similarities in the diseases' mechanisms. This move aligns with Quoin's strategy to broaden QRX003's applications in rare and orphan diseases.

Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focusing on rare and orphan diseases, has announced plans to release its second quarter 2024 financial results before market opening on Thursday, August 8, 2024. The upcoming announcement will include an operational update highlighting the company's achievements during the quarter, along with financial highlights. This pre-market release will provide investors and analysts with important information about Quoin's performance and progress in its specialized field of rare disease therapeutics.

Quoin Pharmaceuticals (NASDAQ: QNRX) announces the international expansion of its clinical trials for Netherton Syndrome. The first international site will open at a research hospital in Saudi Arabia, which is currently treating eligible Netherton patients. An experienced local Clinical Research Organization will manage the study. The site will operate under Quoin's IND application with the US FDA. Additional international sites are also being planned. CEO Dr. Michael Myers highlighted that this expansion aims to accelerate patient recruitment and diversify the patient population. Quoin is conducting two ongoing trials evaluating QRX003, a topical lotion, for Netherton Syndrome.

Quoin Pharmaceuticals (NASDAQ: QNRX) announced its sponsorship of the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference in Albuquerque, NM, from June 28-30, 2024. As a Bronze Sponsor, Quoin will support this biennial event aimed at educating and connecting individuals affected by ichthyosis and other skin disorders. Quoin's COO, Denise Carter, emphasized the company's commitment to raising awareness and developing treatments for rare diseases, including their ongoing clinical trials for QRX003, a topical lotion targeting Netherton Syndrome. The company will also sponsor the conference's celebration dinner on June 29, 2024.

Quoin Pharmaceuticals (NASDAQ: QNRX) has signed a research agreement with University College Cork (UCC) to develop novel topical formulations of Rapamycin (sirolimus) targeting rare and orphan diseases. The focus is on using UCC's proprietary dissolvable microneedle technology to enhance local drug delivery and therapeutic effectiveness. This research program, funded by Quoin, aims to create innovative treatments for diseases lacking approved therapies. Quoin will have the option to advance clinical development without paying upfront fees or royalties. UCC's microneedles dissolve upon skin penetration, offering advantages like painless administration and minimal trauma.

Quoin Pharmaceuticals, a specialty pharmaceutical company, announced positive clinical developments in Netherton Syndrome, including FDA clearance for teen recruitment and protocol amendments for ongoing studies. The company extended its cash runway into late 2025 and expanded its patent portfolio. Financially, Quoin had $14.7 million in cash, with a net loss of $2.3 million for the first quarter of 2024.